Skip to content
★ Sign in to follow
MC
Total declarations
4
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (3 ops.)
€1.4M

Latest filing published 20 Sept 2019 for Hiscox Ltd, €753k.

Filing timeline

BuySale
Mary Childs

Insider track record

Disclosed buys
0
Disclosed sells
3
Signal history

Mary Childs: trading record in brief

Mary Childs appears in our data through filings on Hiscox Ltd shares, published by RNS (LSE). We count 4 filings; the first trade dates from 27 February 2017 and the latest from 18 September 2019.

Sales make up the whole of the open-market record (3 sales, €1.4M). 2019 to date brings no purchases and 1 sale.

The latest filing, published on 20 September 2019, reports an open-market sale of €753k in Hiscox Ltd. Between a trade and the moment it shows up on RNS (LSE), the median delay is 3 days. For comparison, UK MAR gives managers three business days to notify a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.

Companies and markets linked to Mary Childs

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations4 total
  • ▼
    PCA to Robert Childs, ChairmanExecutivesHiscox Ltd
    666,177 GBP33FCA-NSM
    40,600 shares@ £16.4083100.0% of flowLONDON STOCK EXCHANGE, XLONISIN BMG4593F1389FCA-NSM:LSE20190920143523_14235781_20200326185202867_12808-3
  • ●
    PCA to ChairmanExecutivesHiscox Ltd
    0FCA-NSM
    22,400 sharesOutside of Trading PlatformISIN BMG4593F1389FCA-NSM:LSE20171114124403_13431193_20200330131534477_11615-2
  • ▼
    PCA of Robert Childs - ChairmanExecutivesHiscox Ltd
    563,101 GBP27FCA-NSM
    50,000 shares@ £11.26246.3% of flowXLONISIN BMG4593F1389FCA-NSM:LSE20170419155454_13197711_20200330131500005_12315-1
  • ▼
    PCA of Robert Childs - ChairmanExecutivesHiscox Ltd
    13,123 GBP19FCA-NSM
    1,224 shares@ £10.72151.1% of flowXLONISIN BMG4593F1389FCA-NSM:LSE20170301164009_13144346_20200330131525973_1365-1

4 of 4 declarations